Hologic has completed a previously announced deal of Gynesonics, a privately-held company focused on development of minimally invasive solutions for women’s health. The transaction was valued at about $350 million.

The acquisition deal was first announced in October 2024.

Gynesonics’ Sonata system is meant for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, included those related to heavy menstrual bleeding.

The technology merges real-time intrauterine ultrasound guidance with targeted radiofrequency (RF) ablation in a procedure that doesn’t require an incision.

“We are excited to complete the acquisition of Gynesonics and to increase access to their Sonata System, which complements and expands our range of minimally invasive solutions for heavy periods and fibroids,” said Brandon Schnittker, president of Surgical Solutions at Hologic. “As global champions for women’s health, we are dedicated to empowering surgeons with diverse, cutting-edge treatment options as we strive to transform women’s lives for the better.”

“As we embark on this new phase with Hologic, we are excited to see the continued success of the Sonata System, which has already made a difference in the lives of thousands of women,” said Skip Baldino, president and CEO of Gynesonics. “Hologic’s commitment to women’s health and their leadership in innovation make them a perfect fit for our organization.”

Last month, Hologic entered an agreement with the with the Centers for Disease Control and Prevention (CDC) to develop analyte-specific reagents (ASRs) that would aid in detection of H5N1 bird flu.